Historically, dose selection of anticancer drugs has mainly been based on establishing the
maximum tolerated dose in phase 1 clinical trials with a traditional 3 plus 3 design. In the era …

Colorectal cancer (CRC) is the third most common and second most lethal type of cancer
worldwide, presenting major health risks as well as economic costs to both people and …

Background Because adverse reactions or drug resistance are often found after current
chemotherapies for metastatic colorectal cancer (mCRC), new treatments are still in …

This study reports the design, synthesis, and characterization of a novel series of benzene
sulfonamide-triazole hybrid derivatives, to evaluate their anti-cancer potential against …

In this study, new 2-indolinone-indole hybrid compounds (4a-s) carrying a benzoyl moiety
were synthesized and their cytotoxic effects were examined against pancreatic (MIA-PaCa …

Background Most tyrosine kinase inhibitors (TKIs) have failed in clinical trials for metastatic
colorectal cancer (mCRC). To leverage the additional lower-affinity targets that most TKIs …

Colorectal cancer (CRC) may display innate or acquired chemoresistance, and each is
important in determining initial and subsequent lines of systemic treatment. Innate resistance …

The tumor microenvironment is a complex ecosystem that drives cancer progression and
restrains immunity. Although immune checkpoint inhibitors have shown strong potential in a …

Classic ANOVA (cA) tests the explanatory power of a partitioning on a set of objects. More fit
for clusters proximity analysis, nonparametric ANOVA (npA) extends to a case where instead …

The role of mast cells (MCs) in the development and progression of colorectal cancer has
long been investigated. A high density of these immune cells, which are able to release …